EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience

Tingting Chen, Lifei Liang, Siyue Chen, Qing Xu, Xiaoyu Li, Ming Xu, Ruiming Rong, Tongyu Zhu, Cheng Yang

Organ Medicine · 2025

DOI: 10.1002/orm2.70002 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background The study aims to evaluate the preliminary efficacy and safety of basiliximab in treating acute T cell‐mediated rejection (TCMR) after kidney transplantation, particularly in patients with poor responses to standard treatments. Methods We conducted a retrospective case series study involving eight kidney transplant recipients at Zhongshan Hospital, Fudan University, who received basiliximab for anti‐TCMR treatment. Baseline characteristics, immunosuppression management data, and treatment outcomes were collected. Results Among the eight patients, two had biopsy‐proven TCMR. Elevated serum soluble IL‐2R (sIL‐2R) level were detected in all patients before basiliximab treatment. Following basiliximab therapy, all patients exhibited a rapid decrease in sIL‐2R levels, and most cases showed a general downward trend in serum creatinine levels. Although two patients developed pulmonary infections posttreatment, no clear correlation was found between the use of basiliximab and infections. No other new infections or adverse reactions were reported. Conclusions Basiliximab therapy demonstrates efficacy and good tolerance in patients with TCMR.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →